Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 14 June 2026

Drug Delivery Science

Peptide Drug Delivery: From Injection to Oral & Beyond

Why delivering peptides to the body is one of pharmaceutical science's greatest challenges — and how technologies like SNAC, nanoparticles, and engineered absorption enhancers are making non-injectable peptides a reality.

Last updated: March 2026•18 min read

The Delivery Challenge

Peptides are among the most promising therapeutic molecules in modern medicine, yet delivering them to the body remains one of pharmacology's greatest challenges. The fundamental problem is that peptides are, by their nature, designed to be broken down — the same enzymes that digest dietary proteins will rapidly degrade therapeutic peptides.

The Three Barriers

Enzymatic Degradation

Proteolytic enzymes in the stomach (pepsin, pH 1.5–3.5), small intestine (trypsin, chymotrypsin, elastase), and bloodstream (DPP-4, NEP) rapidly cleave peptide bonds. Most unprotected peptides are destroyed within minutes of oral ingestion.

Mucosal Barrier

The intestinal epithelium presents a physical barrier. Tight junctions between enterocytes prevent paracellular transport of large, hydrophilic molecules like peptides. Transcellular transport is limited by the peptide's size and polarity.

First-Pass Metabolism

Even if a peptide survives the gut, it must pass through the portal circulation and liver before reaching the systemic circulation. Hepatic enzymes can further degrade the molecule, dramatically reducing bioavailability.

The result of these barriers is that most peptide drugs have oral bioavailability well below 1%. For comparison, small-molecule drugs like paracetamol achieve oral bioavailability of 60–90%. This is why the vast majority of peptide therapeutics — including insulin, semaglutide (Ozempic/Wegovy), and tirzepatide (Mounjaro) — are administered by injection.

Injectable Delivery

Injection remains the gold standard for peptide delivery because it bypasses all three barriers completely. Subcutaneous injection delivers the peptide directly into the adipose tissue beneath the skin, from where it is absorbed into the bloodstream via capillaries and lymphatic vessels.

Injection Routes Compared

Route	Absorption Speed	Bioavailability	Common Use
Subcutaneous (SC)	Moderate (minutes to hours)	65–100%	Most peptide drugs (semaglutide, insulin)
Intramuscular (IM)	Faster than SC	75–100%	Vaccines, some hormones
Intravenous (IV)	Immediate	100%	Hospital settings, emergencies

Modern Injection Devices

The patient experience of peptide injection has improved dramatically. Modern auto-injector pens (like those used for Wegovy and Mounjaro) use hidden needles, spring-loaded mechanisms, and pre-filled cartridges that make self-injection straightforward. Many patients report that the injection is virtually painless due to the ultra-fine 31-gauge needles used.

Despite these improvements, injection remains a barrier to adoption. Survey data consistently shows that needle phobia and injection burden are the primary reasons patients decline or discontinue injectable therapies. This is the driving force behind the pursuit of non-injectable delivery technologies.

Oral Peptide Delivery

Oral delivery is the "holy grail" of peptide pharmaceutics. Patients overwhelmingly prefer tablets to injections, and oral formulations enable wider prescribing by GPs rather than specialists. The challenge is overcoming the enzymatic and absorption barriers described above.

SNAC Technology: The Rybelsus Breakthrough

The first major breakthrough in oral peptide delivery came with oral semaglutide (Rybelsus), approved for type 2 diabetes. It uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) as a permeation enhancer.

How SNAC Works

1. Gastric pH buffering: SNAC creates a localised alkaline microenvironment around the tablet, protecting semaglutide from pepsin degradation in the acidic stomach.
2. Transcellular enhancement: SNAC promotes absorption of semaglutide across the gastric epithelium via a transcellular route, primarily in the stomach rather than the intestine.
3. Concentration-dependent: The 300mg SNAC tablet delivers only 0.4–1% of the semaglutide dose into the bloodstream — which is why oral semaglutide requires a much higher dose (14mg) compared to injectable (1mg).

Limitations of Current Oral Approaches

Oral semaglutide works, but it illustrates the challenges that remain. The bioavailability is approximately 0.4–1%, meaning 99% of the drug is wasted. Patients must take it on an empty stomach, with no more than 120ml of water, and wait 30 minutes before eating. These strict conditions are necessary to maximise the already-poor absorption and represent a significant adherence burden.

Other Oral Delivery Strategies

Enteric Coating

Polymer coatings that resist stomach acid and dissolve only in the alkaline environment of the small intestine. Protects acid-labile peptides from gastric degradation but does not solve the absorption barrier.

Protease Inhibitors

Co-formulating peptides with enzyme inhibitors (e.g., aprotinin, soybean trypsin inhibitor) to reduce proteolytic degradation in the gut lumen. Effective in vitro but limited by dilution effects in vivo.

Mucoadhesive Systems

Formulations that adhere to the intestinal mucosa, prolonging contact time and creating a high local peptide concentration near the epithelium. Used in some experimental insulin delivery systems.

Cell-Penetrating Peptides

Short peptide sequences (e.g., TAT, penetratin) that can cross biological membranes and carry therapeutic cargo with them. An active research area for improving transcellular peptide transport.

Nasal & Pulmonary Delivery

The nasal mucosa offers several advantages for peptide delivery: a large surface area (~160 cm²), rich blood supply, avoidance of first-pass metabolism, and — critically — a direct route to the central nervous system via the olfactory and trigeminal nerve pathways.

Nasal Peptide Delivery

Peptide	Nasal Bioavailability	Status
Desmopressin (DDAVP)	3–5%	Approved (diabetes insipidus)
Calcitonin (Miacalcin)	3–5%	Approved (osteoporosis)
Oxytocin (Syntocinon)	~2%	Approved (lactation)
Semax	Variable	Approved in Russia (cognitive)
Selank	Variable	Approved in Russia (anxiolytic)

Nasal delivery is particularly appealing for neuropeptides because it can achieve higher brain concentrations than systemic administration. Studies with intranasal insulin, oxytocin, and vasopressin have shown measurable cerebrospinal fluid levels within 30 minutes of nasal dosing, suggesting direct nose-to-brain transport.

Pulmonary Delivery

The lungs offer an enormous surface area (~100 m²), thin alveolar epithelium (0.1–0.2 µm), and extensive blood supply. Inhaled insulin (Exubera, later Afrezza) demonstrated that pulmonary peptide delivery is technically feasible, achieving bioavailability of 10–15%. However, Exubera was a commercial failure due to device size, cost, and concerns about pulmonary function monitoring. Afrezza (Technosphere insulin) uses a smaller device and has found a niche market but remains limited.

Transdermal & Topical Delivery

The skin is an effective barrier against molecules larger than approximately 500 Da. Most therapeutic peptides exceed this cutoff by a considerable margin (semaglutide, for example, is approximately 4,114 Da), making passive transdermal delivery essentially impossible for systemic therapy.

However, transdermal delivery remains highly relevant for two applications:

Topical/Local Effects

Cosmetic peptides like GHK-Cu, Matrixyl, and Argireline are designed to act on the skin itself rather than enter systemic circulation. These smaller peptides (typically <1,000 Da) can penetrate the stratum corneum sufficiently to reach their targets in the dermis and epidermis. This is why topical peptide skincare products can be effective for localised skin benefits even without systemic absorption.

Microneedle Technology

Dissolving microneedle patches contain arrays of tiny needles (typically 250–800 µm long) that painlessly penetrate the stratum corneum and dissolve to release their peptide cargo into the viable epidermis. This technology is in clinical trials for insulin, PTH (parathyroid hormone), and GLP-1 agonist delivery.

Other emerging transdermal technologies include iontophoresis (using mild electrical current to drive charged peptides across the skin), sonophoresis (using ultrasound to temporarily disrupt the skin barrier), and thermal ablation (using brief heat pulses to create micropores in the stratum corneum).

Next-Generation Technologies

Beyond incremental improvements to existing delivery routes, several transformative technologies are in development that could fundamentally change how peptide drugs are administered.

Nanoparticle Encapsulation

Peptides encapsulated in polymeric nanoparticles (PLGA, chitosan), liposomes, or solid lipid nanoparticles are protected from enzymatic degradation while crossing the intestinal epithelium via M-cell-mediated transcytosis or receptor-mediated endocytosis. Oral insulin nanoparticle formulations have achieved bioavailabilities of 5–15% in animal models.

Intestinal Injection Devices

MIT and Novo Nordisk developed SOMA (Self-Orienting Millimetre-scale Applicator), an ingestible capsule that orients itself against the gastric wall and injects a solid peptide needle directly into the stomach lining. Animal studies achieved insulin bioavailability comparable to subcutaneous injection. Human trials are ongoing.

Long-Acting Depot Formulations

Subcutaneous implants or depot injections that release peptides over weeks to months. Technologies include biodegradable polymer microspheres, in-situ forming gels, and osmotic pump implants. These could reduce injection frequency from weekly to monthly or even quarterly.

Gene Therapy Approaches

Rather than delivering the peptide itself, gene therapy approaches aim to engineer the patient's own cells to produce therapeutic peptides endogenously. AAV-mediated GLP-1 gene therapy has shown sustained glucose lowering in diabetic mice for over 6 months. This represents the most radical departure from traditional drug delivery.

The Pipeline: What's Coming

The race to develop non-injectable incretin therapies is one of the most active areas in pharmaceutical development. Several oral GLP-1 agonists are in late-stage clinical trials:

Compound	Company	Type	Phase	Key Feature
Oral semaglutide (high dose)	Novo Nordisk	GLP-1 agonist	Phase III	25–50mg doses for obesity (vs 14mg for T2D)
Orforglipron	Eli Lilly	Oral non-peptide GLP-1 agonist	Phase III	Small molecule — no SNAC needed, no fasting required
Danuglipron	Pfizer	Oral non-peptide GLP-1 agonist	Phase III	Twice-daily small molecule
Amycretin	Novo Nordisk	Oral GLP-1/amylin co-agonist	Phase II	Dual mechanism in oral form — 13% weight loss in Phase I

Orforglipron is particularly noteworthy because it is a small molecule, not a peptide. By mimicking the shape of GLP-1 at the receptor binding site using a non-peptide scaffold, it avoids the enzymatic degradation and absorption challenges entirely. If successful, it would represent a paradigm shift — achieving the effects of a peptide drug without actually using a peptide.

Note: Pipeline compounds are not approved for use and may not complete clinical development. Efficacy and safety data from early trials may not be replicated in larger Phase III studies. None of these compounds are currently available in the UK outside of clinical trials.